Advisor in a private placement
DBV Technologies, creator of Viaskin®, a new standard in the treatment of allergy, launched a private placement for a target amount of circa €25 million, which €14 million will be in the form of new shares and€11 million will be in the form of existing shares. DBV Technologies may extend this amount but will in no event place more than 4,722,464 shares consisting of new shares issued by means of a capital increase without shareholders' preemptive rights and existing shares sold by certain shareholders. The shares will be offered in a Private Placement conducted by way of an accelerated bookbuilding. The issuance of new shares by the Company is intended to raise gross proceeds of around €14 million, which will be used to provide additional funding to the Company to finance its development strategy.